ReviewMechanismInconclusiveModerate evidenceTier 4 · clinical
Advances and technical standards in neurosurgery · Jan 2026
pineal region tumorsgerm cell tumorspineal parenchymal tumorspineocytomapineal parenchymal tumor of intermediate differentiation (PPTID)pineoblastomagerminomapapillary tumor of the pineal region
This review chapter summarizes the histopathological features and molecular alterations of pineal-region tumors. It describes the main tumor groups (germ cell tumors and pineal parenchymal tumors), lists PPT subtypes (pineocytoma, PPTID, pineoblastoma), and highlights molecular findings such as microRNA biogenesis and RB pathway alterations in pineoblastoma, KBTBD4 insertions in PPTIDs, MAPK pathway mutations in germinomas, and chromosome 10 loss in papillary tumor of the pineal region.
Key findings
- Pineal region tumors are rare, accounting for about 1% of central nervous system tumors.
- The two most common pineal-region tumor types are germ cell tumors (GCTs) and pineal parenchymal tumors (PPTs).
- PPTs include pineocytomas (well-differentiated), PPTIDs (intermediate differentiation), and pineoblastomas (poorly differentiated/high-grade).
- Pineoblastoma molecular pathogenesis involves alterations in microRNA biogenesis and the retinoblastoma (RB) pathway.
- PPTIDs are characterized by small in-frame insertions in KBTBD4.
- Pineal germ cell tumors likely originate from overmigrated primordial germ cells and show the same histopathological spectrum as gonadal counterparts; germinomas frequently present mutations in the MAPK pathway.
- Papillary tumor of the pineal region is a distinct ependymal-type tumor that shows loss of chromosome 10 in most cases.
Limitations: This is a narrative review/chapter and does not present original experimental or patient-level data.; Pineal-region tumors are rare (≈1%), so underlying studies and evidence are limited by tumor rarity.; The abstract provides no methodological details, sample sizes, or systematic review methods.; The abstract summarizes molecular associations but does not provide prognostic or therapeutic outcome data..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewReported positiveLimited evidenceTier 4 · clinical
Advances and technical standards in neurosurgery · Jan 2026 · narrative review
pineal region tumorspineal parenchymal tumors (PPTs)pineocytomapineal parenchymal tumor of intermediate differentiation (PPTID)pineoblastoma (PB)papillary tumor of the pineal region (PTPR)desmoplastic myxoid tumor, SMARCB1-mutantgerminomanon-germinomatous germ cell tumor (NGGCT)
This narrative review summarizes current radiotherapy principles for pineal region tumors (various pineal parenchymal tumors and germ cell tumors). It reports recommended radiation approaches and doses by subtype (e.g., adjuvant RT 50-54 Gy for some PPTs, CSI with boost for pineoblastoma, WVI 24 Gy + boost for germinomas) and notes survival outcomes reported in the literature (e.g., >90% 5-year OS for germinoma; >70% 5-year OS for older children with pineoblastoma). The authors highlight use of conformal and particle techniques and call for further dose-volume and biomarker-driven refinement.
Reported effects: adjuvant RT dose (pineocytoma) · adjuvant RT dose (PPTID) · +8 more
Studied with: surgery, chemotherapy.
Key findings
- For pineocytoma (WHO grade I), gross total resection (GTR) provides excellent outcomes; adjuvant radiotherapy (50-54 Gy) or stereotactic radiosurgery (SRS) is reserved for subtotally resected cases.
- PPTIDs (grades II-III): GTR is the main prognostic factor; adjuvant RT (50-54 Gy) improves overall survival; CSI (23-36 Gy + boost) is indicated for disseminated disease.
- Pineoblastoma requires multimodal therapy: CSI (36 Gy + boost to 54-55.8 Gy) combined with chemotherapy yields 5-year OS rates >70% in children ≥3 years, but outcomes are poorer in younger or metastatic patients.
- Papillary tumor of the pineal region (PTPR) often recurs locally; adjuvant focal RT (~50 Gy) is recommended.
- Desmoplastic myxoid tumor, SMARCB1-mutant: limited data, but focal RT ≥54 Gy has been used.
- Pure germinomas are highly radiosensitive and achieve >90% 5-year OS; reduced-volume RT (whole-ventricular irradiation, WVI, 24 Gy + boost) has replaced historical CSI for many cases.
- Non-germinomatous germ cell tumors (NGGCTs) require combined chemotherapy and RT; CSI + boost achieves 70-90% 5-year OS.
- Proton therapy and other particle techniques are increasingly used to reduce long-term neurocognitive and secondary malignancy risks.
- Overall management relies on an integrated approach combining surgery, radiotherapy, and chemotherapy, with growing use of molecular classification to guide risk-adapted treatment.
Limitations: This is a narrative review (no original patient-level data or meta-analytic synthesis reported in the abstract).; Pineal region tumors are rare and heterogeneous, limiting the quality and quantity of evidence for some subtypes.; For some entities (e.g., desmoplastic myxoid tumor, SMARCB1-mutant) the abstract notes limited data supporting management recommendations.; Recommendations appear to be based on aggregated/prior literature rather than prospective randomized data (noted indirectly by review format)..
This review summarizes radiotherapy approaches and reported outcomes for pineal region tumors and is directly relevant to clinical radiotherapy planning for these neoplasms.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialMixed resultsModerate evidenceTier 4 · clinicaln = 77
Neuro-oncology · Oct 2025 · phase 3 randomized controlled trial
Methotrexateembryonal brain tumorsmedulloblastomaGroup 3 medulloblastomaSHH medulloblastomaembryonal tumor with multilayered rosettespineoblastoma This phase 3 randomized trial tested adding high-dose methotrexate to induction chemotherapy in children ≤36 months with high-risk embryonal brain tumors. Overall complete response rates were similar between arms, but in medulloblastoma patients methotrexate was associated with higher CR (63% vs 30%) and improved 5-year event-free survival in Group 3 medulloblastoma (70% vs 33.3%). No benefit was seen for embryonal tumor with multilayered rosettes or pineoblastoma.
Reported effects: eligible patients 77, n=77 · patients evaluated for response 59, n=59 · +8 more
Studied with: induction chemotherapy, high-dose consolidation chemotherapy with hematopoietic stem-cell infusion.
Key findings
- Of 77 eligible patients, 59 with detectable disease were evaluated for response and 28 (47.5%) achieved CR; 15/30 (50%) treated with methotrexate compared to 13/29 (45%) without methotrexate (P = 0.35).
- For medulloblastoma (MB), CR was 12/19 (63%) with methotrexate compared to 6/20 (30%) without methotrexate (P = 0.039).
- All SHH subtype MB (n = 11) were survivors (molecular characterization retrospective).
- Five-year event-free survival (EFS) for Group 3 MB was 70% (90% CI: 39.6-87.2) with methotrexate versus 33.3% (90% CI: 15.0-52.9) without (P = 0.037).
- In other embryonal tumors, CR was 3/11 (27%) with methotrexate compared to 7/9 (78%) without (P = 0.99).
- No benefit observed for Embryonal Tumor with Multilayered Rosettes (n = 14; EFS 20.0% [90% CI: 1.8-52.5] with methotrexate versus 33.3% [90% CI: 10.8-58.1] without, P = 0.58) or pineoblastoma (n = 9; EFS 16.7% [90% CI: 1.6-46.1] with methotrexate versus 0% without, P = 0.52).
Limitations: Relatively small overall sample size (77 eligible) with smaller numbers in histologic/molecular subgroups; Molecular characterization was conducted retrospectively; Some subgroup analyses involve very small n (e.g., Group 3 MB: 10 vs 15; SHH MB n=11); Tests of significance were one-sided (as stated); Confidence intervals reported are 90% rather than the more conventional 95%.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Animal studyMechanismReported positivePreclinical onlyTier 2 · animal
Genes & development · Jun 2025 · genetically engineered mouse models
pineoblastoma
Researchers used genetically engineered mouse models that represent different molecular subtypes of pineoblastoma to examine the roles of miRNA-processing enzymes Drosha and Dicer1. They found that loss of either Drosha or Dicer1 partially mimicked the tumorigenic effects of Rb1 deletion by promoting cell cycle progression via derepression of Plagl2 and cyclin D2. The study reports a novel mechanism in which disrupted miRNA processing can drive pineoblastoma development and notes that targeting downstream proliferative drivers could be a potential therapeutic strategy.
Key findings
- Multiple genetically engineered mouse models representing distinct molecular subtypes of pineoblastoma were developed.
- Loss of either Drosha or Dicer1 partially mimicked the tumorigenic effects of Rb1 deletion.
- Loss of Drosha or Dicer1 promoted cell cycle progression through derepression of Plagl2 and cyclin D2.
- Disrupted miRNA processing is reported as a novel mechanism driving pineoblastoma development.
- Authors highlight a potential therapeutic strategy of targeting downstream proliferative drivers.
Limitations: Study was performed in mouse models only (no human interventional data reported).; Abstract provides no sample size, statistical details, or quantitative results.; Therapeutic strategy is suggested but not tested in this report..
Direct investigation of molecular drivers of pineoblastoma using mouse models; mechanistic relevance to tumorigenesis.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Animal studyMechanismReported positivePreclinical onlyTier 2 · animal
Genes & development · Jun 2025
pineoblastomapineal tumor
The authors deleted Drosha or Dicer1 in the developing mouse pineal gland to model microRNA-defective pineoblastoma. These mice developed pineal tumors with loss of microRNAs (notably let-7/miR-98-5p), derepression of microRNA target genes, and upregulation of S-phase genes and developmental homeobox transcription factors. Blocking tumor proliferation promoted expression of pinealocyte maturation markers and reduced some embryonic markers, and inhibiting signaling downstream of the oncofetal transcription factor Plagl2 impaired tumor growth. The study suggests that targeting downstream proliferation drivers may limit growth of tumors caused by loss of microRNA processing.
Key findings
- Ablation of Drosha or Dicer1 in the developing pineal gland of mice produces pineal tumors characterized by loss of microRNAs, particularly the let-7/miR-98-5p family, and derepression of microRNA target genes.
- Pineal tumors driven by Drosha or Dicer1 loss show upregulation of S-phase genes and homeobox transcription factors and phenocopy tumors driven by Rb1 loss.
- Blocking proliferation in these tumors facilitates expression of pinealocyte maturation markers and reduces some embryonic markers, although select embryonic markers remain elevated due to continued absence of the repressing microRNAs.
- Plagl2 is identified as a microRNA target and an oncofetal transcription factor that regulates progrowth genes; inhibiting Plagl2-related signaling impairs tumor growth.
Limitations: Animal (mouse) genetic-ablation model only — findings not demonstrated in human patients.; Study models genetic loss of microRNA processing (Drosha/Dicer1 ablation), which may not fully recapitulate the diversity of human tumor genetics.; No clinical or human data reported to support translational efficacy or safety of targeting the identified pathways..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismReported positiveLimited evidenceTier 4 · clinical
Cancers · Feb 2025
pineoblastoma
This review summarizes recent advances in pineoblastoma research, describing major molecular subtypes driven by DICER/DROSHA loss, RB1 loss, or cMYC activation and noting differing prognoses between them. It reports that mouse models have been developed for RB1-, DICER1- and DROSHA-driven subtypes (a MYC-driven model is not yet established) and discusses tumor cell of origin, progression, autophagy, and potential targetable vulnerabilities while highlighting that metastatic disease is incurable and standard treatments can impair neurocognitive function.
Key findings
- Pineoblastoma comprises several major molecular subtypes: (i) loss of microRNA processing factors DICER and DROSHA, (ii) loss of RB1, and (iii) amplification/induction of cMYC.
- The DICER/DROSHA subtype is characterized by a relatively good prognosis whereas RB1- and MYC-driven subtypes exhibit exceedingly poor prognosis.
- Mouse models have recently been established for RB1-, DICER1- and DROSHA-driven pineoblastoma subtypes; a MYC-driven mouse model has not yet been established.
- The review discusses disease biology including cell of origin, tumor progression, the role of autophagy, and describes targetable vulnerabilities that could inform future precision therapies.
- Standard treatment (surgery, radiation, systemic chemotherapy) improves survival but compromises neurocognitive function; metastatic pineoblastoma is described as incurable.
Limitations: This article is a review and does not present new primary experimental or clinical data.; Many conclusions discussed are based on recent preclinical models and not yet validated in humans.; A MYC-driven pineoblastoma mouse model has not been established, limiting preclinical study of that high-risk subtype.; Pineoblastoma is a rare disease, which limits available clinical data and may hinder generalizability of findings..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 108
Frontiers in oncology · Dec 2024 · systematic review
pineoblastoma
This systematic review pooled 108 adult pineoblastoma cases from 32 articles and analyzed survival outcomes. The reported 5-year survival rate was 49.5% and the 10-year survival rate was 33.9%. Gross total resection was associated with better survival than subtotal resection or no surgery (P=0.018), and radiotherapy and chemotherapy were associated with improved survival (P<0.001; P=0.020); radiotherapy was an independent favorable factor in multivariate analysis (P<0.001).
Reported effects: total cases included 108, n=108 · median age at diagnosis 30, n=108 · +7 more
Key findings
- Total of 108 adult cases from 32 articles; median age at diagnosis was 30 years.
- 5-year survival rate was 49.5% (95% confidence interval: 0.378-0.602).
- 10-year survival rate was 33.9% (95% confidence interval: 0.207-0.476).
- During 10-year follow-up, gross total resection was more beneficial than subtotal resection and no surgery (P=0.018).
- Radiotherapy and chemotherapy were associated with improved survival (P<0.001; P=0.020).
- Multivariate COX analysis identified radiotherapy as an independent factor for beneficial prognosis (P<0.001); gross total resection tended to improve 5-year survival (P=0.079).
Limitations: Small total case number (n=108) compiled from heterogeneous sources (case reports, single-institution series).; Retrospective and observational data; no randomized controlled trials included.; Potential selection and reporting bias across included studies.; Heterogeneity of treatments and follow-up across studies limits causal inference..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMixed resultsLimited evidenceTier 4 · clinical
Neuro-oncology · Dec 2024 · consensus review
pineal parenchymal tumorspineocytomapineal parenchymal tumor of intermediate differentiationpineoblastomapapillary tumor of the pineal region
This international consensus review summarizes diagnostic and treatment approaches for rare pineal parenchymal tumors and related intrinsic pineal masses. It highlights recent genomic findings that informed refinements in the WHO 5th edition molecular classification and offers pragmatic clinical management recommendations ranging from surgery alone to intensive multimodal antineoplastic therapy.
Key findings
- Pineal parenchymal tumors are rare and lack robust evidence-based treatment recommendations.
- These tumors vary in biology, clinical characteristics, and prognosis, necessitating a range of treatments from surgical resection alone to intensive multimodal antineoplastic therapy.
- Recent international genomic studies have refined the molecular-based disease classification, incorporated in the WHO 5th edition.
- The review summarizes literature on diagnostic and therapeutic approaches and suggests pragmatic recommendations for clinical management of intrinsic pineal region masses (pineocytoma, PPTID, pineoblastoma), pineal cyst, and papillary tumors of the pineal region.
Limitations: Tumors are rare and high-quality evidence is sparse, limiting strength of recommendations.; Recommendations are based on literature review and consensus rather than randomized controlled trials.; Heterogeneity of tumor biology and prognosis may limit generalizability of suggested management approaches.; No new primary quantitative data are reported in this review..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text